1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
PeptiDream Inc.

PeptiDream Inc.

4587.T
PeptiDream Inc.JP flagTokyo Stock Exchange
1,070.00
JPY
+21.00
- -
137.49BMarket Cap
PeptiDream Inc.
4587.T
(Tokyo Stock Exchange)

Recent

price

1,070.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3.14
7.62
7.64
22.62
38.94
42.84
53.26
58.41
- -
92.92
73.09
206.83
221.37
360.14
143.21
427.58
Revenue per Share
0.12
1.54
1.39
9.18
14.23
16.54
19.35
22.42
- -
35.4
19.96
58.19
23.41
115.85
-28.99
167.35
Basic EPS, GAAP
-2.42
1.37
-0.01
1.35
-3.92
-3.53
-12.01
34.69
- -
9.12
42.2
-31.26
85.21
166.86
-116.23
-6.03
Free Cash Flow per Basic Share
0.19
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
3.09
53.77
54.56
62.6
90.74
106.41
120
139.41
135.65
168.77
195.26
246.79
311.32
437.94
398.78
453.44
Book Value per Share
3.09
53.77
54.56
62.57
89.8
105.35
119.05
138.47
134.72
168.14
194.68
165.12
229.67
356.82
318.39
372.33
Tangible Book Value per Share
86
89
107
109
111
114
121
124
- -
126
129
130
130
130
129
130
Basic Weighted Avg Shares
269
678
819
2,474
4,328
4,896
6,427
7,217
- -
11,677
9,422
26,852
28,712
46,677
18,521
55,420
Sales/Revenue/Turnover
-6.76
23.71
24.59
56.22
58.88
50.87
45.29
49.6
- -
59.87
43.16
33.44
23.59
45.23
-27.07
58.48
Operating Margin (%)
42
52
74
103
143
195
513
521
- -
571
633
1,973
2,433
2,248
2,127
2,367
Depreciation Expense
10
137
149
1,004
1,581
1,891
2,335
2,770
- -
4,448
2,573
7,554
3,036
15,015
-3,749
21,690
Net Income, GAAP
- -
21.21
33.1
32.76
33.16
27.95
25.91
27.23
- -
26.11
32.35
- -
30.27
28.12
- -
28.19
Effective Tax Rate (%)
3.71
20.23
18.14
40.58
36.54
38.62
36.34
38.39
- -
38.09
27.31
28.13
10.57
32.17
-20.24
39.14
Profit Margin (%)
222
5,531
5,699
5,538
6,901
7,174
6,345
7,931
7,361
10,935
12,460
14,042
18,608
38,803
15,501
43,532
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
18,358
19,634
17,042
- -
18,339
LT Debt
327
5,696
5,863
6,912
10,243
12,181
14,709
17,449
16,978
21,217
25,350
32,041
40,350
56,762
51,528
58,771
Total Equity
- -
4.13
2.31
14.06
18.52
15.33
15.53
15.52
- -
25.88
11.39
- -
7.94
20.51
- -
33.25
Return on Invested Capital (%)
- -
4.55
2.57
15.72
18.44
16.86
17.37
17.23
- -
23.29
11.05
- -
7.97
22.29
- -
35.82
Return on Capital (%)
- -
4.55
2.57
15.72
18.44
16.86
17.37
17.23
- -
23.29
11.05
26.33
8.39
30.92
-6.92
48.31
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
2,586
2,588
2,590
LT Borrowings
19,634
18,987
18,339
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
130
130
130
Market Capitalization
192,662
184,497
322,863

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
27,225
35,372
61,782
Cash, Cash Equivalents & STI
19,514
27,341
25,484
Accounts Receivable, Net
4,971
4,729
32,766
Inventories
2,404
2,738
2,790
Total Current Liabilities
8,617
10,100
18,250
Payables & Accruals
- -
- -
- -
ST Debt
2,586
2,588
2,590
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.38%
20.65%
-9.22%
Free Cash Flow
- -
-49.25%
-169.51%
Net Income, GAAP
- -
72.25%
-124.97%
Sales/Revenue/Turnover
- -
34.97%
-60.32%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,225
31,908
- -
- -
46,677
2025
- -
- -
- -
- -
18,521
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-6.5
144.8
- -
- -
115.85
2025
- -
- -
- -
- -
-28.99
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Nkarta, Inc. (NKTX)
Locus Cell Co., Ltd. (6891.TWO)
AlloVir, Inc. (ALVR)
BLIS Technologies Limited (BLT.NZ)
Aptahem AB (publ) (APTA.ST)
Amicogen, Inc. (092040.KQ)
Business
PeptiDream Inc. (4587.T), a public biopharmaceutical company founded in 2006 and headquartered in Kawasaki, Japan, engages in the discovery, development and commercialization of constrained peptides, small molecules and peptide-drug conjugate therapeutics; macrocyclic peptide-based therapeutics and diagnostics; peptide-drug conjugates including radioligand therapies and multi-functional peptide conjugates; and radiopharmaceutical and radio-diagnostic products. The company leverages its proprietary Peptide Discovery Platform System (PDPS) to generate non-standard peptide libraries for identifying potent, selective macrocyclic peptide candidates targeting oncology, immunology, metabolic disorders, neuromuscular conditions, infectious diseases and allergic indications, with a development pipeline featuring PD-L1 (Ph1), PD-L1 BMS-986229 (Ph1), CD38 BHV-1100 + NK cells for multiple myeloma (Ph1), GhR AZP-3813 for acromegaly/NET (Ph1), preclinical programs including Glypican-3 for liver cancer, Myostatin for DMD/muscle disorders, TfR for neuromuscular disorders, c-Kit for allergic conditions, c-Met and HA-protein for influenza. PeptiDream operates primarily through its Drug Discovery and Development segment via strategic research collaborations, technology licensing of PDPS and pipeline expansion with global pharmaceutical partners including Novartis, MSD (Merck), Genentech and Bristol Myers Squibb, serving therapeutic areas across oncology, central nervous system disorders and metabolic diseases with worldwide geographic reach. Recent developments include a 2024 expansion of its long-standing peptide discovery collaboration with Novartis granting exclusive global rights for radioligand therapy programs using PDPS-optimized macrocyclic peptides conjugated with radionuclides, featuring $180 million upfront payment and up to $2.7 billion in milestones plus royalties; ongoing multi-target partnerships such as with MSD for peptide drug conjugates; and pipeline advancements including multiple Phase 1 clinical programs.